Top in endocrinology: Osteoporosis in menopause, obesity treatment landscape
Click Here to Manage Email Alerts
New research showed that absolute appendicular lean mass may help predict osteoporosis in postmenopausal women. It was the top story in endocrinology last week.
Another top story was about the effectiveness of the injectable obesity treatment semaglutide (Wegovy, Novo Nordisk) and how the drug is changing the treatment landscape amid a global rise in obesity prevalence.
Read these and more top stories in endocrinology below:
Absolute appendicular lean mass best predictor of osteoporosis in menopause
Absolute appendicular lean mass appears to be a suitable marker for predicting osteoporosis based on low muscle mass for postmenopausal women, according to findings published in Menopause. Read more.
‘A new era’: How semaglutide could change the obesity treatment landscape
The prevalence of overweight and obesity continues to rise in the United States and globally at an alarming rate. By 2025, data from the NCD Risk Factor Collaboration suggest 18% of men and 21% of women globally will have obesity. Read more.
Vitamin D sufficiency may reduce MI all-cause mortality risk in primary prevention
Treating to a vitamin D level of at least 30 ng/mL is associated with significantly lower risk for myocardial infarction and all-cause mortality among adults with no prior MI history, according to an analysis of Veterans Affairs data. Read more.
Liraglutide reduces visceral, ectopic fat in obesity with high CV risk
Adults with obesity at high cardiovascular risk saw significant reductions in visceral and ectopic fat after adding daily liraglutide 3 mg to a reduced-calorie diet and lifestyle plan, findings from a randomized controlled trial show. Read more.
Does intergenerational transmission of obesity begin in the womb or home?
Fetal and infant environments do not cause type 2 diabetes or obesity. Instead, these environments make type 2 diabetes and obesity much more likely because they change the sensitivity of the individual to the obesogenic and metabolic milieu after birth. Read more.